STAT+: Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies

Georg Schett, known for CAR-T work, moves in a new direction Georg SchettBoulevard Bio Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01. Over the last five years, German researcher Georg Schett has made a name for himself as a pioneer in autoimmune disease treatment, showing that CAR-T therapy could be used to reset patients’ immune systems. He has become a scientific adviser de rigueur for the field, joining a half-dozen startup advisory boards. Now, for the first time, he’s co-founding a biotech company. But it has no immediate plans to work in CAR-T. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Biotech Startups and Venture Capital Reporter Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01.